News

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Grail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test ...
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.